Literature DB >> 21087210

Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1.

Ayaz Najafov1, Eeva M Sommer, Jeffrey M Axten, M Phillip Deyoung, Dario R Alessi.   

Abstract

PDK1 (3-phosphoinositide-dependent protein kinase 1) activates a group of protein kinases belonging to the AGC [PKA (protein kinase A)/PKG (protein kinase G)/PKC (protein kinase C)]-kinase family that play important roles in mediating diverse biological processes. Many cancer-driving mutations induce activation of PDK1 targets including Akt, S6K (p70 ribosomal S6 kinase) and SGK (serum- and glucocorticoid-induced protein kinase). In the present paper, we describe the small molecule GSK2334470, which inhibits PDK1 with an IC₅₀ of ~10 nM, but does not suppress the activity of 93 other protein kinases including 13 AGC-kinases most related to PDK1 at 500-fold higher concentrations. Addition of GSK2334470 to HEK (human embryonic kidney)-293, U87 or MEF (mouse embryonic fibroblast) cells ablated T-loop residue phosphorylation and activation of SGK isoforms and S6K1 induced by serum or IGF1 (insulin-like growth factor 1). GSK2334470 also inhibited T-loop phosphorylation and activation of Akt, but was more efficient at inhibiting Akt in response to stimuli such as serum that activated the PI3K (phosphoinositide 3-kinase) pathway weakly. GSK2334470 inhibited activation of an Akt1 mutant lacking the PH domain (pleckstrin homology domain) more potently than full-length Akt1, suggesting that GSK2334470 is more effective at inhibiting PDK1 substrates that are activated in the cytosol rather than at the plasma membrane. Consistent with this, GSK2334470 inhibited Akt activation in knock-in embryonic stem cells expressing a mutant of PDK1 that is unable to interact with phosphoinositides more potently than in wild-type cells. GSK2334470 also suppressed T-loop phosphorylation and activation of RSK2 (p90 ribosomal S6 kinase 2), another PDK1 target activated by the ERK (extracellular-signal-regulated kinase) pathway. However, prolonged treatment of cells with inhibitor was required to observe inhibition of RSK2, indicating that PDK1 substrates possess distinct T-loop dephosphorylation kinetics. Our data define how PDK1 inhibitors affect AGC signalling pathways and suggest that GSK2334470 will be a useful tool for delineating the roles of PDK1 in biological processes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21087210     DOI: 10.1042/BJ20101732

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  64 in total

Review 1.  Atypical protein kinase Cι as a human oncogene and therapeutic target.

Authors:  Peter J Parker; Verline Justilien; Philippe Riou; Mark Linch; Alan P Fields
Journal:  Biochem Pharmacol       Date:  2013-11-11       Impact factor: 5.858

2.  Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer Cells.

Authors:  Claudia Ctortecka; Vinayak Palve; Brent M Kuenzi; Bin Fang; Natalia J Sumi; Victoria Izumi; Silvia Novakova; Fumi Kinose; Lily L Remsing Rix; Eric B Haura; John Matthew Koomen; Uwe Rix
Journal:  Mol Cell Proteomics       Date:  2018-09-14       Impact factor: 5.911

3.  A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1.

Authors:  T Justin Rettenmaier; Jack D Sadowsky; Nathan D Thomsen; Steven C Chen; Allison K Doak; Michelle R Arkin; James A Wells
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-17       Impact factor: 11.205

Review 4.  PI3K signaling in cancer: beyond AKT.

Authors:  Evan C Lien; Christian C Dibble; Alex Toker
Journal:  Curr Opin Cell Biol       Date:  2017-03-24       Impact factor: 8.382

5.  Fine-tuning the intensity of the PKB/Akt signal enables diverse physiological responses.

Authors:  Xiangyu Zhou; Lluis Cordon-Barris; Tinatin Zurashvili; Jose Ramon Bayascas
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

6.  Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation.

Authors:  Grace M Wang; Hong Yuen Wong; Hiroyuki Konishi; Brian G Blair; Abde M Abukhdeir; John P Gustin; D Marc Rosen; Samuel Ray Denmeade; Zeshaan Rasheed; William Matsui; Joseph P Garay; Morassa Mohseni; Michaela J Higgins; Justin Cidado; Danijela Jelovac; Sarah Croessmann; Rory L Cochran; Sivasundaram Karnan; Yuko Konishi; Akinobu Ota; Yoshitaka Hosokawa; Pedram Argani; Josh Lauring; Ben Ho Park
Journal:  Cancer Res       Date:  2013-04-11       Impact factor: 12.701

7.  CD28 and CD3 have complementary roles in T-cell traction forces.

Authors:  Keenan T Bashour; Alexander Gondarenko; Haoqian Chen; Keyue Shen; Xin Liu; Morgan Huse; James C Hone; Lance C Kam
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

8.  Insulin augments serotonin-induced contraction via activation of the IR/PI3K/PDK1 pathway in the rat carotid artery.

Authors:  Shun Watanabe; Takayuki Matsumoto; Mirai Oda; Kosuke Yamada; Junya Takagi; Kumiko Taguchi; Tsuneo Kobayashi
Journal:  Pflugers Arch       Date:  2015-11-17       Impact factor: 3.657

Review 9.  PDK1 inhibitors.

Authors:  Elisa Barile; Surya K De; Maurizio Pellecchia
Journal:  Pharm Pat Anal       Date:  2012-05

10.  TPCK inhibits AGC kinases by direct activation loop adduction at phenylalanine-directed cysteine residues.

Authors:  Rana Anjum; Eunice Pae; John Blenis; Bryan A Ballif
Journal:  FEBS Lett       Date:  2012-08-10       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.